Updates are available Correction dated 2025-05-22
Click to view Correction: https://doi.org/10.1038/s41467-025-60137-1
-
Authors
Wang, Yong
Wang, Yanan
Bao, Lei
Vale, Goncalo https://orcid.org/0000-0003-1104-0289
McDonald, Jeffrey G. https://orcid.org/0000-0003-1570-4142
Fang, Yisheng
Peng, Yan
Kumar, Ashwani
Xing, Chao https://orcid.org/0000-0002-1838-0502
Brasó-Maristany, Fara https://orcid.org/0000-0001-5440-9643
Prat, Aleix
Arteaga, Carlos L. https://orcid.org/0000-0003-0870-9586
Wang, Yingfei https://orcid.org/0000-0002-8723-252X
Luo, Weibo https://orcid.org/0000-0002-1992-0320
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA222393)
Cancer Prevention and Research Institute of Texas (RR140036, RP190358)
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 11 April 2025
First Online: 25 April 2025
Change Date: 22 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-60137-1
Competing interests
: Yong Wang, Yingfei Wang, and W.L. are inventors on provisional patent application US 63/676,270. F.B.-M. has filed patents, including PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369. A.P. reports stockholder and consultant roles at Reveal Genomics, advisory role for Roche, AstraZeneca, Novartis, and Daiichi-Sankyo, and grant funding from Roche, AstraZeneca, Novartis, and Daiichi-Sankyo. C.L.A. serves as scientific advisor to Novartis, Lilly, Merck, Daiichi Sankyo, OrigiMed, Sanofi, AstraZeneca, PUMA Biotechnology, TAIHO Oncology, Arvinas, Athenex, Laekna Therapeutics, and the Susan G. Komen Foundation, and has received research grant support from Pfizer, Lilly, and Takeda. None of these activities are related or relevant to the work presented herein. The other authors declare no competing interests.
